Stay updated with breaking news from ரேம் செல்வராஜு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Repligen Corp (RGEN) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Christopher Missling [Audio gap] the quest for disease-confined therapies for neurodegenerative disorders. Separately, the independent Data Monitoring Safety Board, DSMB, also like the ongoing clinical trial program, including the late-stage AVATAR RS-002, EXCELLENCE RS-003, and the US Rett syndrome extension study, RS-EP-001 of Anavex 2-73 has also completed its recent pre-planned review of the respective interim safety data for these three separate clinical studies. Upon review of the interim safety data, the DSMB made the following recommendation for each of the three studies. The DSMB recommendation is to continue the studies without modifications. This is very good news and indicates we re on the right path with all these studies. As a reminder, our clinical strategy is to clearly differentiate from other biopharma companies and clinical studies in CNS. Anavex is continuing to pioneer the approach of big data, including Anavex in clinical trials to leverage the level ....
Good morning, and welcome to the Axsome Therapeutics Conference Call. [Operator Instructions] I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Please go ahead. Mark Jacobson Chief Operating Officer Thank you, operator. Good morning, and thank you all for joining us on today s conference call. Our earnings press release providing a corporate update and details of the company s financial results for the first quarter of 2021 crossed the wire a short time ago and is available on our website at axsome.com. During today s call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct in the source of future clinical trials, regulatory plans, ....